On May 21, 2025, Scotiabank analyst Sung Ji Nam reaffirmed the "Sector Outperform" rating for Castle Biosciences (CSTL, Financial), maintaining the previous rating, indicating continued positive expectations for the company's performance within its sector.
Despite maintaining the rating, the analyst has revised the price target for Castle Biosciences (CSTL, Financial) from $44.00 to $40.00. This adjustment reflects a decrease of 9.09% in the expected price target, showing a more cautious outlook on the stock's potential valuation.
The current price target set by Scotiabank suggests potential room for growth in the stock price, aligning with the maintained "Sector Outperform" rating, which typically indicates an expectation for the stock to perform better than the overall sector average.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Castle Biosciences Inc (CSTL, Financial) is $35.89 with a high estimate of $41.00 and a low estimate of $30.00. The average target implies an upside of 120.58% from the current price of $16.27. More detailed estimate data can be found on the Castle Biosciences Inc (CSTL) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Castle Biosciences Inc's (CSTL, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Castle Biosciences Inc (CSTL, Financial) in one year is $30.03, suggesting a upside of 84.57% from the current price of $16.27. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Castle Biosciences Inc (CSTL) Summary page.
